Bryn Mawr Trust Advisors LLC Takes $765,000 Position in Zimmer Biomet Holdings, Inc. $ZBH

Posted by George Bondi on Aug 15th, 2026

Bryn Mawr Trust Advisors LLC acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 8,883 shares of the medical equipment provider’s stock, valued at approximately $765,000.

Other large investors also recently bought and sold shares of the company. Mill Capital Management LLC purchased a new stake in shares of Zimmer Biomet in the 2nd quarter valued at approximately $464,000. Tema ETFs LLC lifted its stake in Zimmer Biomet by 39.8% during the second quarter. Tema ETFs LLC now owns 4,194 shares of the medical equipment provider’s stock worth $361,000 after purchasing an additional 1,194 shares in the last quarter. Kentucky Trust Co grew its stake in shares of Zimmer Biomet by 285.0% in the second quarter. Kentucky Trust Co now owns 770 shares of the medical equipment provider’s stock valued at $66,000 after buying an additional 570 shares in the last quarter. Handelsbanken Fonder AB raised its holdings in shares of Zimmer Biomet by 22.7% in the 2nd quarter. Handelsbanken Fonder AB now owns 152,064 shares of the medical equipment provider’s stock valued at $13,091,000 after buying an additional 28,130 shares during the period. Finally, Valeo Financial Advisors LLC lifted its stake in Zimmer Biomet by 1.6% during the 2nd quarter. Valeo Financial Advisors LLC now owns 11,176 shares of the medical equipment provider’s stock worth $962,000 after acquiring an additional 175 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Stock Up 1.0%

Zimmer Biomet stock opened at $100.52 on Friday. The stock has a 50 day moving average of $91.51 and a two-hundred day moving average of $90.54. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $108.29. The stock has a market capitalization of $19.17 billion, a price-to-earnings ratio of 24.46, a PEG ratio of 3.17 and a beta of 0.45. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.53 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, June 25th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend was Thursday, June 25th. Zimmer Biomet’s payout ratio is currently 23.36%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. Citigroup lowered their target price on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. Citizens Jmp decreased their price objective on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a research note on Wednesday, April 29th. Barclays reduced their target price on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a report on Wednesday, April 29th. Finally, Canaccord Genuity Group lifted their price objective on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and an average price target of $104.42.

Read Our Latest Stock Analysis on Zimmer Biomet

About Zimmer Biomet

(Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.